Medtronic to Unveil Pivotal Trial Results for Hybrid Closed Loop System at American Diabetes Association 2016 Meeting
07 June 2016 - 11:00PM
DUBLIN - June 7, 2016 -
Medtronic plc (NYSE:MDT), the global leader in medical technology,
today announced its schedule of notable sessions that will be
presented at the 76th Scientific Sessions of the American Diabetes
Association in New Orleans. Among the presentations are late
breaking pivotal trial results of the Hybrid Closed Loop
system, pivotal trial results for the company's fourth generation
sensor and further study of the company's SmartGuard(TM)
technology. Hybrid Closed Loop system is approved for
investigational use only in the U.S., and many devices being
presented at ADA are also investigational use only.
"At ADA 2016, we have a number of important data
presentations about our marketed products and key products in our
pipeline, most notably our Hybrid Closed Loop system and next
generation sensor," said Francine R. Kaufman, M.D., chief medical
officer and vice president of global, clinical and medical affairs
for Medtronic Diabetes. "We are proud to be the first company to
present results of a pivotal trial of a closed loop system, which
is designed to automatically control glucose levels 24 hours a day
with less input from patients, as we continue toward our goal of
helping people with diabetes enjoy greater freedom and better
health."
"The ability for people with diabetes to achieve
better glucose control and live longer, healthier lives has
significantly improved with insulin pumps and continuous glucose
monitoring systems. However, patients must still make frequent
decisions each day while using today's systems," said Richard M.
Bergenstal, M.D., of the International Diabetes Center in
Minneapolis. "Simplifying this self-management and adding a little
peace of mind with this more automated Hybrid Closed Loop system
would impact these patients' lives in a very meaningful way."
Scientific
Presentations
Closing the Loop
-
"Pivotal Trial of a Hybrid Closed-Loop System in
Type 1 Diabetes (T1D)" will be moderated by Dr. Richard Bergenstal
on Sunday, June 12 from noon to 2 p.m. 99-LB.
-
"Overnight Closed-Loop (OCL) at Home Compared
with Sensor-Augmented Pump with Low-Glucose Suspend (SAP-LGS)
Improves Time in Target Range in Adults and Reduces Hypoglycemia in
Adolescents" will be presented by Dr. Amin Sharifi on Saturday,
June 11 from 8:15-8:30 a.m. 78-OR.
-
"Quantitative Evaluation of a Predictive
Low-Glucose Management (PLGM) System" will be presented by Dr.
Bruce Buckingham on Saturday, June 11 at 9:30-9:45 a.m.
83-OR.
-
"Glucose Concentrations and Rates of Change
during Hypoglycemia Induction to Evaluate a Predictive Low Glucose
Management (PLGM) System" will be moderated by Dr. Satish Garg on
Saturday, June 11 from 11:30 a.m. to 12:30 p.m. and Sunday, June 12
from noon to 2 p.m. 985-P.
-
"Incremental Benefits of Predictive vs.
Responsive Low Glucose Suspension Strategies in Automated Insulin
Delivery Systems" will be moderated by Dr. Chantal McMahon on
Sunday, June 12 from noon to 2 p.m. 998-P.
-
"Hypoglycemia Reduction in Sensor-Augmented Pump
Therapy (SAP) with Predictive Low Glucose Management
(SmartGuard(TM)) in Children with Type 1 Diabetes" will be
moderated by Dr. Olga Kordonouri on Monday, June 13 from noon to 1
p.m. 871-P.
Sensing
The conference will showcase advancements of Medtronic continuous
glucose monitoring (CGM) technology with intelligent diagnostics
and sensor redundancy, resulting in market-leading accuracy,
usability and reliability for both stand-alone and closed-loop CGM
systems.
-
"Accuracy of a Fourth-Generation Glucose Sensor
at Different Anatomical Locations" will be moderated by Dr. Bruce
Bode on Sunday, June 12 from noon to 2 p.m. 879-P.
-
"Accuracy of a Fourth-Generation Glucose Sensor
Throughout its Functional Life" will be moderated by Dr. Ronald
Brazg on Sunday, June 12 from noon to 2 p.m. 897-P.
-
"Accuracy of a Fourth-Generation Glucose Sensor
Paired with Different Real-Time Display Devices" will be moderated
by Dr. Mark Christiansen on Sunday, June 12 from noon to 2 p.m.
901-P.
-
"Fourth-Generation Glucose Sensor for Use in
Standalone CGM and Sensor Augmented Pump Systems" will be presented
by Ashley Sullivan on Sunday, June 12 from noon to 2 p.m.
916-P.
-
"Fifth-Generation Glucose Sensor System with
Extended Wear and Fewer Calibrations" will be moderated by Dr.
Johanna Ulloa on Sunday, June 12 from noon to 2 p.m. 905-P.
Health Economics
Type 2 Diabetes
Company
Presentations
Medtronic will host a series of presentations at Booth #301 from
Saturday through Monday, where the audience will get the
opportunity to hear from experts regarding the application of
Medtronic technologies in their practice.
-
Transforming Data into Actions with Personalized
Diabetes Insights: Saturday, June 11 at 10:30 a.m.; Sunday, June 12
at 3 p.m.; Monday, June 13 at 1 p.m.
-
Advances in the Use of iPro2 in Type 2 Diabetes:
Saturday, June 11 at 1 p.m. and Sunday, June 12 at 1:30
p.m.
-
Improving Outcomes Through Automation with
SmartGuard Technology: Saturday, June 11 at 3 p.m.; Sunday, June 12
at 10:30 a.m.; Monday, June 13 at 10:30 a.m.
Analyst and Investor
Briefing
Medtronic will host a webcast to provide an update on its Diabetes
Group during the conference on Sunday, June 12 from 2 p.m. to
approximately 4 p.m. CDT. The webcast will feature remarks from
Medtronic management, including comments on Medtronic's clinical
data, product pipelines, and market outlooks. The live audio
webcast can be accessed at http://investorrelations.medtronic.com
on June 12. Within 24 hours of the webcast, a replay will be
available by clicking on the Investor Events link at
http://investorrelations.medtronic.com. This event is not part
of the official ADA Scientific Sessions.
About the Diabetes Group at
Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 85,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
Pamela Reese
Public Relations
+1-818-576-3398
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
HUG#2018380
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2024 to May 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From May 2023 to May 2024